421 related articles for article (PubMed ID: 17342407)
1. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?
Katsel P; Li C; Haroutunian V
Neurochem Res; 2007; 32(4-5):845-56. PubMed ID: 17342407
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa.
Dany M; Elston D
J Am Acad Dermatol; 2017 Aug; 77(2):268-273.e6. PubMed ID: 28551069
[TBL] [Abstract][Full Text] [Related]
3. Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases.
Custodia A; Romaus-Sanjurjo D; Aramburu-Núñez M; Álvarez-Rafael D; Vázquez-Vázquez L; Camino-Castiñeiras J; Leira Y; Pías-Peleteiro JM; Aldrey JM; Sobrino T; Ouro A
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897658
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Wójtowicz S; Strosznajder J; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2020 Jun; 57(6):2799-2811. PubMed ID: 32356173
[TBL] [Abstract][Full Text] [Related]
5. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis.
Han X; M Holtzman D; McKeel DW; Kelley J; Morris JC
J Neurochem; 2002 Aug; 82(4):809-18. PubMed ID: 12358786
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of sphingolipid metabolism in Alzheimer's disease.
He X; Huang Y; Li B; Gong CX; Schuchman EH
Neurobiol Aging; 2010 Mar; 31(3):398-408. PubMed ID: 18547682
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.
Fonteh AN; Ormseth C; Chiang J; Cipolla M; Arakaki X; Harrington MG
PLoS One; 2015; 10(5):e0125597. PubMed ID: 25938590
[TBL] [Abstract][Full Text] [Related]
8. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease.
Yuyama K; Mitsutake S; Igarashi Y
Biochim Biophys Acta; 2014 May; 1841(5):793-8. PubMed ID: 23948264
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Huanglian Jiedu Decoction on Microglia with Abnormal Sphingolipid Metabolism in Alzheimer's Disease.
Qi YY; Heng X; Yao ZY; Qu SY; Ge PY; Zhao X; Ni SJ; Guo R; Yang NY; Zhang QC; Zhu HX
Drug Des Devel Ther; 2022; 16():931-950. PubMed ID: 35391788
[TBL] [Abstract][Full Text] [Related]
10. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis.
Haughey NJ; Bandaru VV; Bae M; Mattson MP
Biochim Biophys Acta; 2010 Aug; 1801(8):878-86. PubMed ID: 20452460
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside and related-sphingolipid profiles are altered in a cellular model of Alzheimer's disease.
Noel A; Ingrand S; Barrier L
Biochimie; 2017 Jun; 137():158-164. PubMed ID: 28365364
[TBL] [Abstract][Full Text] [Related]
12. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.
Cutler RG; Kelly J; Storie K; Pedersen WA; Tammara A; Hatanpaa K; Troncoso JC; Mattson MP
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2070-5. PubMed ID: 14970312
[TBL] [Abstract][Full Text] [Related]
13. Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2019 Jan; 56(1):174-185. PubMed ID: 29687345
[TBL] [Abstract][Full Text] [Related]
14. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain.
Bandaru VV; Troncoso J; Wheeler D; Pletnikova O; Wang J; Conant K; Haughey NJ
Neurobiol Aging; 2009 Apr; 30(4):591-9. PubMed ID: 17888544
[TBL] [Abstract][Full Text] [Related]
15. Modulation of sphingolipid metabolism with calorie restriction enhances insulin action in skeletal muscle.
Obanda DN; Yu Y; Wang ZQ; Cefalu WT
J Nutr Biochem; 2015 Jul; 26(7):687-95. PubMed ID: 25771159
[TBL] [Abstract][Full Text] [Related]
16. Role of Intracellular Lipid Logistics in the Preferential Usage of Very Long Chain-Ceramides in Glucosylceramide.
Yamaji T; Horie A; Tachida Y; Sakuma C; Suzuki Y; Kushi Y; Hanada K
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775668
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis.
Ellis B; Hye A; Snowden SG
J Alzheimers Dis; 2015; 46(2):313-27. PubMed ID: 25835424
[TBL] [Abstract][Full Text] [Related]
18. Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease.
Mizuno S; Ogishima S; Kitatani K; Kikuchi M; Tanaka H; Yaegashi N; Nakaya J
PLoS One; 2016; 11(2):e0148431. PubMed ID: 26849355
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?
Mielke MM; Lyketsos CG
Neuromolecular Med; 2010 Dec; 12(4):331-40. PubMed ID: 20571935
[TBL] [Abstract][Full Text] [Related]
20. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease.
Wang M; Roussos P; McKenzie A; Zhou X; Kajiwara Y; Brennand KJ; De Luca GC; Crary JF; Casaccia P; Buxbaum JD; Ehrlich M; Gandy S; Goate A; Katsel P; Schadt E; Haroutunian V; Zhang B
Genome Med; 2016 Nov; 8(1):104. PubMed ID: 27799057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
